ZWZhuohua Wen

Zhuohua Wen

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Zhuohua Wen has a total of 86 co-authors. Here are the top co-authors by number of shared publications:

  • Xin Feng

    Neurosurgery Center, Department of Cerebrovascular Surgery, Engineering Technology Research Center of Education Ministry of China on Diagnosis and Treatment of Cerebrovascular Disease, Zhujiang Hospital, Southern Medical University, Guangzhou, China

    8 shared publications
  • Chuanzhi Duan

    Zhujiang Hospital, Southern Medical University

    7 shared publications
  • Mengshi Huang

    Neurosurgery Center, Department of Cerebrovascular Surgery, Engineering Technology Research Center of Education Ministry of China on Diagnosis and Treatment of Cerebrovascular Disease, Zhujiang Hospital, Southern Medical University, Guangzhou, China

    6 shared publications
  • Aihua Liu

    Beijing Neurosurgical Institute, Beijing Tiantan Hospital, Capital Medical University

    5 shared publications
  • Chi Huang

    Neurosurgery Center, Department of Cerebrovascular Surgery, Engineering Technology Research Center of Education Ministry of China on Diagnosis and Treatment of Cerebrovascular Disease, Zhujiang Hospital, Southern Medical University, Guangzhou, China

    5 shared publications
  • Runze Ge

    Neurosurgery Center, Department of Cerebrovascular Surgery, Engineering Technology Research Center of Education Ministry of China on Diagnosis and Treatment of Cerebrovascular Disease, Zhujiang Hospital, Southern Medical University, Guangzhou, China

    5 shared publications

Latest Publications

  • Pipeline Shield versus Pipeline Flex for unruptured intracranial aneurysms: a propensity-matched multicenter study

    by Runze Ge, Chao Peng, Wenxin Chen, Guangzhong Chen, Can Li, Peifeng Guan, Lele Dai, Zhuohua Wen, Chi Huang, Jiwan Huang, et al.

    Background Pipeline Flex Embolization Device with Shield Technology (PED Shield) is designed to reduce the incidence of thrombosis events through phosphorylcholine coating. However, the comparative efficacy and safety of PED Shield and PED/PED Flex remain unclear. Methods We conducted a retrospective analysis of a prospectively maintained database at three advanced stroke centers from February 2016 to October 2024. Propensity score matching was employed to adjust for sex, age, hypertension, diabetes, hyperlipidemia, smoking, aneurysm location, morphology, size, coiling and follow-up duration. After matching, perioperative complications and clinical and angiographic outcomes were compared. Results 1039 patients treated by PED/PED Flex and 172 patients treated by PED Shield were enrolled. For clinical outcomes, 164 pairs were matched. No significant differences were found in total perioperative complications (7.9% vs. 4.9%, p = 0.259) and favourable prognosis (mRS score 0–2, 98.0% vs. 97.5%, p = 0.760) between the PED Shield and PED/PED Flex group. For angiographic outcomes, 121 pairs were matched. No significant differences were observed in complete occlusion (80.2% vs. 73.6%, p = 0.223), significant in-stent stenosis (ISS, ISS rate > 50%) (3.3% vs. 5.0%, p = 0.749) and symptomatic ISS (0.0% vs. 2.5%, p = 0.247) between the PED Shield and PED/PED Flex group. However, PED Shield had a lower incidence of ISS (ISS rate ≥ 25%, 5.0 vs. 14.9%, p = 0.010) at a mean follow-up time of 6–7 months. Conclusion Compared with PED/PED Flex, PED Shield has a lower rate of ISS at a mean follow-up time of 6–7 months. No significant differences are observed in perioperative complications, clinical outcomes, complete occlusion, significant ISS and symptomatic ISS. Registration URL: https://www.clinicaltrials.gov; Unique identifier: NCT06446778.

  • Development and validation of the FLATS score to predict periprocedural ischemic events after stent-assisted coiling for ruptured intracranial aneurysms in the acute phase: a nationwide chinese registry

    by Chi Huang, Hailong Zhong, Yiming Bi, Weiming Zhong, Zhuohua Wen, Yihan Chen, Chenxi Duan, Yueyi Zhang, Mengshi Huang, Zhicen Li, et al.

    Aneurysmal subarachnoid hemorrhage (aSAH) is a devastating stroke subtype. In the acute phase (< 72 h), stent-assisted coiling (SAC) carries a

  • Sex difference in predictors of aneurysmal wall enhancement: a cross-sectional and prospective cohort study

    by Runze Ge, Jiwan Huang, Caihong Li, Yuxin Li, Zhuohua Wen, Anqi Xu, Mengshi Huang, Jiancheng Lin, Hao Yuan, Hongyu Shi, et al.

    Background Aneurysm wall enhancement (AWE) is a potential imaging biomarker that can be used to identify intracranial aneurysms with an increased risk of rupture. Factors and mechanisms causing intracranial aneurysms to rupture or progress differ between women and men. Thus, we performed a cross-sectional and prospective cohort study to identify the risk factors predicting AWE in men and women. Methods Consecutive patients with unruptured intracranial aneurysms were prospectively recruited from September 2022 to September 2024. Baseline characteristics were collected through a standard questionnaire. Multivariate logistic regression was performed to assess the predictors of aneurysmal wall enhancement in men and women. Results A total of 332 patients with 435 intracranial aneurysms were included. In the multiple logistic regression analysis, obesity (OR = 2.88, 95% CI 1.06–7.81, P = 0.038), the history of hypertension (OR = 2.76, 95% CI 1.16–6.57, P = 0.022) and younger age (OR = 0.96, 95% CI 0.93-1.00, p = 0.035) were independent risk factors for AWE in men. Meanwhile, drinking habit (OR = 2.64, 95% CI 1.09–6.41, P = 0.032), the family history of intracranial aneurysm (OR = 4.01, 95% CI 1.21–13.36, P = 0.024) and older age (OR = 1.04, 95% CI 1.01–1.07, P = 0.009) were independent risk factors for AWE in women. Conclusion This study clearly demonstrates a significant sexual dimorphism in the risk factors associated with AWE. These findings underscore the necessity for sex-specific risk stratification models for intracranial aneurysm management, suggesting that men and women have specific lifestyle interventions to prevent the progression or rupture of intracranial aneurysms.


  • Open Access

    Effect of LDL-Cholesterol Levels and Oral Atorvastatin on Outcomes After Pipeline Therapy for Intracranial Aneurysms

    by Xin Feng, Chi Huang, Xin Tong, Zhuohua Wen, Yajun Zhu, Mengshi Huang, Jiancheng Lin, Jiwan Huang, Hao Yuan, Anqi Xu, et al.

    BACKGROUND: We aimed to determine the effects of statin treatment on outcomes of pipeline embolization device therapy for intracranial aneurysms in relation to LDL (low-density lipoprotein) cholesterol levels. METHODS: Using data from the SESIA registry (Safety and Efficacy of Stent Deployment for Intracranial Aneurysms), we enrolled participants who underwent pipeline embolization device implantation at 4 centers in China (2018–2022). Statin users (atorvastatin 20 mg daily, for ≥3 days and ≥6 months preprocedurally and postprocedurally, respectively) were matched with nonstatin users (1:1) using propensity scores and further adjusted by inverse probability of treatment weighting, balancing for baseline characteristics, procedural details, and lipid levels (based on East Asian profiles). Study outcomes include perioperative complications, aneurysmal occlusion, in-stent stenosis, and clinical prognosis at the latest follow-up. Multivariable analyses using logistic and Cox regression models adjusted for these factors in both prematched and postmatched cohorts, evaluating the role of lipid modification in subgroups. RESULTS: Of the 1558 patients screened, 1193 (53.75±11.07 years, 69.4% females; statin: n=603, nonstatin: n=590) were enrolled with 3- to 48-month follow-up. In the matched cohort (352 pairs), statin treatment reduced the incidences of perioperative cerebrovascular (2.0% versus 8.5%, P =0.001) and follow-up ischemic (1.7% versus 5.1%, P =0.020) complications. Multivariable analyses in participants with baseline LDL-cholesterol ≥2.59 mmol/L showed that statin treatment was associated with fewer perioperative cerebrovascular complications (odds ratio, 0.371 [95% CI, 0.195–0.705]; P =0.002), in-stent stenosis (hazard ratio, 0.433 [95% CI, 0.269–0.698]; P =0.001), and follow-up ischemic events (hazard ratio, 0.315 [95% CI, 0.135–0.733]; P =0.007; P values for interaction were 0.671, 0.009, and 0.507, respectively, versus <2.59 mmol/L). Postmatched analyses confirmed consistency for perioperative cerebrovascular complications (odds ratio, 0.416 [95% CI, 0.211–0.821]), in-stent stenosis (hazard ratio, 0.397 [95% CI, 0.232–0.667]), and follow-up ischemic events (hazard ratio, 0.364 [95% CI, 0.148–0.895]). CONCLUSIONS: Atorvastatin treatment improved postpipeline embolization device-deployment outcomes by reducing ischemic events, particularly in patients with elevated LDL-cholesterol. The long-term benefits of adjunctive statin use in this population warrant further investigation. REGISTRATION: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT03387995.


  • Hemodynamic analysis of optimal branch selection for flow-diverting stents in middle cerebral artery bifurcation aneurysms: a pilot study

    by Xin Feng, Jiwan Huang, Shiyan Weng, Chi Huang, Mengshi Huang, Zhuohua Wen, Runze Ge, Can Li, Jiancheng Lin, Hao Yuan, et al.

    Background Despite the expanding use of flow-diverting stents (flow diverters—FDs) for middle cerebral artery (MCA) bifurcation aneurysms, their efficacy remains contentious in this complex anatomy. Current studies report conflicting complete occlusion rates (55–92%) and significant branch stenosis/occlusion risks (8–43%), highlighting unmet needs in stent placement strategy. Methods In this retrospective cohort study combining clinical data with computational fluid dynamics (CFD), 20 MCA bifurcation aneurysms (19 patients) treated with FDs were analyzed. Patient-specific models derived from three-dimensional digital subtraction angiography underwent CFD simulations to quantify pre/post-stent hemodynamic changes. Key parameters (inflow rate, wall shear stress, residual flow volume) were compared between aneurysms with complete versus incomplete healing, and the impact of stent placement in branches of varying diameters was analyzed. Results At a median follow-up of 9 months, complete occlusion was achieved in 55% (11/20) and partial occlusion in 25% (5/20). Though not statistically significant, hemodynamic analysis revealed the daughter artery diameter ratio (DR)-stratified efficacy. Stents with a DR between 0.65 and 0.80 placed in smaller-diameter branches more effectively reduced inflow rate, relative inflow rate, and aneurysm wall shear stress. Conversely, stents with a DR between 0.80 and 0.95 were more effective in larger-diameter branches. Conclusion This study indicates that vessel DR could guide intraoperative decisions for FD placement in MCA bifurcations. Prioritizing smaller branches in certain anatomical profiles may enhance flow remodeling without increasing procedural risks. These findings suggest a hemodynamic basis for moving beyond traditional size-based approaches and could inform more precise stent selection in complex bifurcation interventions. Further validation through controlled trials is needed.


  • Open Access

    Safety and Efficacy of Endovascular Thrombectomy for Acute Ischemic Stroke After Cardiac Surgery: A Retrospective Analysis of Readmission Nationwide Database Data

    by Xin Tong, Xiaopeng Xue, Zhuohua Wen, Chuanzhi Duan, Xin Feng, Xiaochuan Huo

    Background: There is limited evidence regarding outcomes of endovascular thrombectomy (EVT) in patients with acute ischemic stroke after cardiac surgery (CS). Therefore, we aimed to evaluate the outcomes of EVT in patients with acute ischemic stroke attributable to CS. Methods AND RESULTS: The data of retrospective study was obtained from the National Readmission Database between 2016 and 2020. Patients with acute ischemic stroke who received EVT within 7 days after CS were compared with 2 groups: those who did not receive EVT after CS (Analysis‐1) and those who received EVT without CS (Analysis‐2). The primary outcome was functional outcome determined by discharge disposition. Propensity score matching was employed to minimize covariate imbalance and subgroup analyses were conducted by type of CS. In the total cohort, 983 patients received EVT treatment after CS, 43 578 patients had non‐EVT treatment after CS, and 66 829 patients received EVT treatment without CS. In the Analysis‐1 outcomes after matching, the EVT treatment after CS had a lower poor functional outcome (57.6% versus 63.7%, P =0.043), more routine discharge (23.5% versus 15.8%, P =0.002), but higher proportion of intracranial hemorrhage (21.50% versus 12.50%, P P =0.084) compared with non‐EVT after CS. In Analysis‐2, no statistical differences were found between EVT after CS and EVT without CS. Conclusions: Favorable findings of short‐term functional outcomes demonstrate that EVT is likely an effective and acceptable treatment modality for patients with acute ischemic stroke following CS . However, the risk of intracranial hemorrhage remains a concern in these patients.


  • Comparison of Tubridge and Pipeline Embolisation Devices in intracranial aneurysms: a multicentre, propensity-matching analysis on the patency of branch vessels

    by Mengshi Huang, Xin Feng, Zhuohua Wen, Chi Huang, Jiwan Huang, Anqi Xu, Xin Tong, Gengwu Ma, Jiancheng Lin, Hongyu Shi, et al.

    To compare the impact of two flow diverter devices (Pipeline Embolization Device [PED] and Tubridge Embolization Device [TED]) on branch vessels patency in intracranial aneurysm treatment, with specific focus on branch vessel outcomes and clinical safety. A retrospective analysis of 320 patients with 430 aneurysms and 602 covered branches treated with PED or TED was conducted. Statistical analyses included descriptive statistics and group comparisons. Potential predictors of aneurysm and branch occlusion were identified through univariate analysis followed by multivariate logistic regression. Propensity score matching was adjusted for baseline discrepancies, and the comparative analysis examined stent efficacy on branch vessels patency and clinical outcomes. Stenosis or occlusion rates were 6.1% for the ophthalmic artery (OA), 31.6% for the posterior communicating artery (PComA), 0.9% for the anterior choroidal artery (AChA), 40.5% for the anterior cerebral artery (ACA), and 0% for the middle cerebral (MCA), lenticulostriate (LSA), posterior inferior cerebellar (PICA), and anterior inferior cerebellar arteries (AICA). Before propensity score matching, branch vessels patency rates did not significantly differ between the PED and TED groups. After matching, 109 pairs were identified. No significant differences in angiographic outcomes for distal and proximal branch vessels regarding occlusion or stenosis were observed between groups (P values > 0.999 and 0.332, respectively). Branch obliteration was mostly asymptomatic. PED and TED showed comparable safety profiles and branch vessel patency rates. These findings indicate that FD treatment may be clinically safe for selected ICA and VA cases requiring branch vessel coverage.


  • Open Access

    A Mendelian randomisation, propensity score matching study to investigate causal association between serum homocysteine and intracranial aneurysm

    by Zhuohua Wen, Xin Feng, Xin Tong, Chao Peng, Anqi Xu, Haiyan Fan, Yiming Bi, Wenchao Liu, Zhenjun Li, Shenquan Guo, et al.

    Background and purpose Recent observational studies have reported that serum total homocysteine (tHcy) is associated with intracranial aneurysms (IAs). However, the causal effect of tHcy on IAs is unknown. We leveraged large-scale genetic association and real-world data to investigate the causal effect of tHcy on IA formation. Methods We performed a two-sample Mendelian randomisation (MR) using publicly available genome-wide association studies summary statistics to investigate the causal relationship between tHcy and IAs, following the recommendations of the Strengthening the Reporting of Observational Studies in Epidemiology-MR statement. Furthermore, a propensity score matching (PSM) analysis was conducted to evaluate the detailed effects of tHcy on risk of IA formation by utilizing real-world multicentre data, including 9902 patients with and without IAs (1:1 matched). Further interaction and subgroup analyses were performed to elucidate how tHcy affects risk of IA formation. Results MR analyses indicated that genetically determined tHcy was causally associated with IA risk (OR, 1.38, 95% CI 1.07 to 1.79; p=0.018). This is consistent with the more conservative weighted median analysis (OR, 1.41, 95% CI 1.03 to 1.93; p=0.039). Further sensitivity analyses showed no evidence of horizontal pleiotropy or heterogeneity of single nucleotide polymorphisms in causal inference. According to the PSM study, we found that, compared with low tHcy (≤15 µmol/L), moderate tHcy (>15–30 µmol/L) (OR 2.13, 95% CI 1.93 to 2.36) and high tHcy (>30 µmol/L) (OR 3.66, 95% CI 2.71 to 4.95) were associated with a higher IA risk (p trend Conclusion Both large-scale genetic evidence and multicentre real-world data support a causal association between tHcy and risk of IA formation. Serum tHcy may serve as a biomarker to identify high-risk individuals who would particularly benefit from folate supplementation.